In lung cancer models, the chemokine monocyte chemoattractant protein-1 (CCL2) positively correlates with MDSC frequency, and antibody-mediated blockade of CCL2 reduces both G-MDSCs and M-MDSCs in tumours reducing iNOS and Arg1 expression [75]. Here, CCL2 is linked to neoplasm.